Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription 08.04.2019 2 Ann Oncol 5 BMC Cancer 2 BMJ 4 Breast Cancer 2 Breast Cancer (Dove Med Press) 2 Breast Cancer Res 6 Breast Cancer Res Treat 3 Breast J 2 Cancer 1 Cancer Lett 2 Cancer Res 2 Clin Breast Cancer 1 Curr Treat Options Oncol 1 Eur J Cancer 1 Eur J Surg Oncol 1 Eur Radiol 1 Gene 2 Int J Oncol 1 Int J Radiat Oncol Biol Phys 2 J Clin Oncol 1 J Natl Cancer Inst 1 Lancet Oncol 1 Oncol Rep 3 Oncology 12 PLoS One 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Oncol

1. MARRA A, Curigliano G
   T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer.
   Ann Oncol. 2019 Apr 2. pii: 5425459. doi: 10.1093.
   PubMed     Text format    
   
   
2. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
   Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
   Ann Oncol. 2019 Mar 30. pii: 5423828. doi: 10.1093.
   PubMed     Text format    
   
   

   
   BMC Cancer

3. MULLAN PB, Bingham V, Haddock P, Irwin GW, et al
   NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.
   BMC Cancer. 2019;19:236.
   PubMed     Text format     Abstract available
   
   
4. SHAHI RB, De Brakeleer S, Caljon B, Pauwels I, et al
   Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
   BMC Cancer. 2019;19:313.
   PubMed     Text format     Abstract available
   
   
5. FERRARO DA, Patella F, Zanivan S, Donato C, et al
   Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells.
   BMC Cancer. 2019;19:312.
   PubMed     Text format     Abstract available
   
   
6. KLEIN J, Tran W, Watkins E, Vesprini D, et al
   Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis.
   BMC Cancer. 2019;19:306.
   PubMed     Text format     Abstract available
   
   
7. CAMPBELL EJ, Dachs GU, Morrin HR, Davey VC, et al
   Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels.
   BMC Cancer. 2019;19:307.
   PubMed     Text format     Abstract available
   
   

   
   BMJ

8. CHRISTIE B
   Tayside breast cancer patients are recalled after treatment is criticised.
   BMJ. 2019;365:l1542.
   PubMed     Text format    
   
   
9. THORNTON H
   Yet another risk score-will it really help decision making?
   BMJ. 2018;362:k3847.
   PubMed     Text format    
   
   

   
   Breast Cancer

10. HIRAOKA E, Mimae T, Ito M, Kadoya T, et al
    Correction to: Breast cancer cell motility is promoted by 14-3-3gamma.
    Breast Cancer. 2019 Mar 29. pii: 10.1007/s12282-019-00964.
    PubMed     Text format     Abstract available
    
    
11. OMORI Y, Enatsu S, Cai Z, Ishiguro H, et al
    Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
    Breast Cancer. 2019 Apr 4. pii: 10.1007/s12282-019-00965.
    PubMed     Text format     Abstract available
    
    
12. KATO F, Kudo K, Yamashita H, Baba M, et al
    Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer.
    Breast Cancer. 2019 Apr 1. pii: 10.1007/s12282-019-00969.
    PubMed     Text format     Abstract available
    
    
13. LEE A, Jo S, Lee C, Shin HH, et al
    Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
    Breast Cancer. 2019 Mar 29. pii: 10.1007/s12282-019-00967.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

14. HOSSEINI S, Chamani J, Hadipanah MR, Ebadpour N, et al
    Nano-curcumin's suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression.
    Breast Cancer (Dove Med Press). 2019;11:137-142.
    PubMed     Text format     Abstract available
    
    
15. NGUYEN HM, Dao MQ
    Detection of human mammaglobin mRNA in breast cancer cells among Vietnamese women.
    Breast Cancer (Dove Med Press). 2019;11:143-150.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

16. BRAVACCINI S, Maltoni R
    CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?
    Breast Cancer Res. 2019;21:49.
    PubMed     Text format    
    
    
17. SHIEH Y, Scott CG, Jensen MR, Norman AD, et al
    Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
    Breast Cancer Res. 2019;21:48.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

18. KUROZUMI S, Joseph C, Raafat S, Sonbul S, et al
    Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05216.
    PubMed     Text format     Abstract available
    
    
19. EVANS DGR, Harkness EF, Brentnall AR, van Veen EM, et al
    Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05210.
    PubMed     Text format     Abstract available
    
    
20. LIN Y, Wang C, Huang X, Zhou X, et al
    Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05207.
    PubMed     Text format     Abstract available
    
    
21. KUSAMA H, Shimoda M, Miyake T, Tanei T, et al
    Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues.
    Breast Cancer Res Treat. 2019 Apr 4. pii: 10.1007/s10549-019-05222.
    PubMed     Text format     Abstract available
    
    
22. KORZETS Y, Fyles A, Shepshelovich D, Amir E, et al
    Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Mar 30. pii: 10.1007/s10549-019-05209.
    PubMed     Text format     Abstract available
    
    
23. WANG G, Qin S, Zayas J, Ingle JN, et al
    4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05194.
    PubMed     Text format     Abstract available
    
    

    
    Breast J

24. SHAH C, Vicini F
    Accelerated partial breast irradiation-Redefining the treatment target for women with early stage breast cancer.
    Breast J. 2019 Apr 4. doi: 10.1111/tbj.13241.
    PubMed     Text format     Abstract available
    
    
25. WANG ZH, Ng HI, Teng CS, Ge ZC, et al
    Outcomes of single-port gasless laparoscopic breast-conserving surgery for breast cancer: An observational study.
    Breast J. 2019 Apr 3. doi: 10.1111/tbj.13249.
    PubMed     Text format     Abstract available
    
    
26. LEINERT E, Schwentner L, Blettner M, Wockel A, et al
    Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: Results from the prospective multicenter BRENDA II study.
    Breast J. 2019 Apr 3. doi: 10.1111/tbj.13231.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

27. RANA HQ, Sacca R, Drogan C, Gutierrez S, et al
    Prevalence of germline variants in inflammatory breast cancer.
    Cancer. 2019 Apr 1. doi: 10.1002/cncr.32062.
    PubMed     Text format     Abstract available
    
    
28. PRINTZ C
    Substituting adjuvant trastuzumab emtansine for Herceptin improves survival in patients with human epidermal growth factor receptor 2-positive breast cancer.
    Cancer. 2019;125:1213.
    PubMed     Text format    
    
    

    
    Cancer Lett

29. DIAZ-RODRIGUEZ E, Perez-Pena J, Rios-Luci C, Arribas J, et al
    TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.
    Cancer Lett. 2019 Mar 27. pii: S0304-3835(19)30198.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

30. ZHANG H, Zhang N, Liu Y, Su P, et al
    Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer.
    Cancer Res. 2019 Apr 2. pii: 0008-5472.CAN-18-3418.
    PubMed     Text format     Abstract available
    
    
31. JUNG SY, Papp JC, Sobel EM, Yu H, et al
    Breast cancer risk and insulin resistance: post genome-wide gene-environment interaction study using a random survival forest.
    Cancer Res. 2019 Apr 1. pii: 0008-5472.CAN-18-3688.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

32. ALTUNDAG K
    Characteristics of Patients With Breast Cancer With Brain Metastases Who Live Longer Than 60 Months.
    Clin Breast Cancer. 2019 Mar 6. pii: S1526-8209(19)30105.
    PubMed     Text format    
    
    
33. LARSEN V, Barlow WE, Yang JJ, Zhu Q, et al
    Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.
    Clin Breast Cancer. 2019 Mar 6. pii: S1526-8209(18)30783.
    PubMed     Text format     Abstract available
    
    

    
    Curr Treat Options Oncol

34. PONDE N, Aftimos P, Piccart M
    Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
    Curr Treat Options Oncol. 2019;20:37.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

35. YUAN P, Hu X, Sun T, Li W, et al
    Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
    Eur J Cancer. 2019;112:57-65.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

36. SAVAGE P, Yu N, Dumitra S, Meterissian S, et al
    The effect of the American Joint Committee on Cancer eighth edition on breast cancer staging and prognostication.
    Eur J Surg Oncol. 2019 Mar 23. pii: S0748-7983(19)30355.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

37. UHLIG J, Uhlig A, Biggemann L, Fischer U, et al
    Diagnostic accuracy of cone-beam breast computed tomography: a systematic review and diagnostic meta-analysis.
    Eur Radiol. 2019;29:1194-1202.
    PubMed     Text format     Abstract available
    
    

    
    Gene

38. MUKUND V, Saddala MS, Farran B, Mannavarapu M, et al
    Molecular docking studies of angiogenesis target protein HIF-1alpha and genistein in breast cancer.
    Gene. 2019;701:169-172.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

39. SEOK J, Yoon SH, Lee SH, Jung JH, et al
    The oncometabolite d2hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway.
    Int J Oncol. 2019;54:753-763.
    PubMed     Text format     Abstract available
    
    
40. AHN EH, Yang H, Hsieh CY, Sun W, et al
    Evaluation of chemotherapeutic and cancer-protective properties of sphingosine and C2-ceramide in a human breast stem cell derived carcinogenesis model.
    Int J Oncol. 2019;54:655-664.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

41. BOULLE G, Saint-Martin C, De La Lande B, Laki F, et al
    Photons without bolus versus electrons with bolus after upfront mastectomy without immediate reconstruction in breast cancer patients.
    Int J Radiat Oncol Biol Phys. 2019 Mar 26. pii: S0360-3016(19)30396.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

42. TOLANEY SM, Guo H, Pernas S, Barry WT, et al
    Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Apr 2:JCO1900066. doi: 10.1200/JCO.19.00066.
    PubMed     Text format     Abstract available
    
    
43. FOLDI J, O'Meara T, Marczyk M, Sanft T, et al
    Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
    J Clin Oncol. 2019 Apr 3:JCO1801933. doi: 10.1200/JCO.18.01933.
    PubMed     Text format    
    
    

    
    J Natl Cancer Inst

44. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

45. DAS M
    Supplemental ultrasonography for breast cancer screening.
    Lancet Oncol. 2019 Mar 28. pii: S1470-2045(19)30211.
    PubMed     Text format    
    
    

    
    Oncol Rep

46. FAN C, Liu N
    Identification of dysregulated microRNAs associated with diagnosis and prognosis in triplenegative breast cancer: An in silico study.
    Oncol Rep. 2019 Apr 2. doi: 10.3892/or.2019.7094.
    PubMed     Text format     Abstract available
    
    

    
    Oncology

47. MERY B, Rowinski E, Vallard A, Jacquin JP, et al
    Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
    Oncology. 2019 Apr 2:1-6. doi: 10.1159/000499583.
    PubMed     Text format     Abstract available
    
    
48. GINZAC A, Passildas J, Gadea E, Abrial C, et al
    Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity.
    Oncology. 2019;96:1-12.
    PubMed     Text format     Abstract available
    
    
49. ROININEN N, Takala S, Haapasaari KM, Jukkola-Vuorinen A, et al
    Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Oncology. 2019;96:147-155.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

50. WANG K, Duan X, Gao F, Wang W, et al
    Dissecting cancer heterogeneity based on dimension reduction of transcriptomic profiles using extreme learning machines.
    PLoS One. 2018;13:e0203824.
    PubMed     Text format     Abstract available
    
    
51. STARLARD-DAVENPORT A, Allman R, Dite GS, Hopper JL, et al
    Validation of a genetic risk score for Arkansas women of color.
    PLoS One. 2018;13:e0204834.
    PubMed     Text format     Abstract available
    
    
52. COTTU PH, Bonneterre J, Varga A, Campone M, et al
    Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
    PLoS One. 2018;13:e0204973.
    PubMed     Text format     Abstract available
    
    
53. KUMAR V, Denis M, Gregory A, Bayat M, et al
    Viscoelastic parameters as discriminators of breast masses: Initial human study results.
    PLoS One. 2018;13:e0205717.
    PubMed     Text format     Abstract available
    
    
54. DHAGE S, Ernlund A, Ruggles K, Axelrod D, et al
    A genomic ruler to assess oncogenic transition between breast tumor and stroma.
    PLoS One. 2018;13:e0205602.
    PubMed     Text format     Abstract available
    
    
55. JOO MW, Kang YK, Ogura K, Iwata S, et al
    Post-radiation sarcoma: A study by the Eastern Asian Musculoskeletal Oncology Group.
    PLoS One. 2018;13:e0204927.
    PubMed     Text format     Abstract available
    
    
56. JINESH GG, Flores ER, Brohl AS
    Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers.
    PLoS One. 2018;13:e0206008.
    PubMed     Text format     Abstract available
    
    
57. ALKARAKOOLY Z, Al-Anbaky QA, Kannan K, Ali N, et al
    Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells.
    PLoS One. 2018;13:e0206182.
    PubMed     Text format     Abstract available
    
    
58. OU J, Si Y, Goh K, Yasui N, et al
    Bioprocess development of antibody-drug conjugate production for cancer treatment.
    PLoS One. 2018;13:e0206246.
    PubMed     Text format     Abstract available
    
    
59. BAATJES KJ, Kotze MJ, McCaul M, Conradie M, et al
    Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
    PLoS One. 2019;14:e0214153.
    PubMed     Text format     Abstract available
    
    
60. ZHANG Y, Chen J, Wang Y, Wang D, et al
    Multilayer network analysis of miRNA and protein expression profiles in breast cancer patients.
    PLoS One. 2019;14:e0202311.
    PubMed     Text format     Abstract available
    
    
61. BURTON LJ, Hawsawi O, Loyd Q, Henderson V, et al
    Association of Epithelial Mesenchymal Transition with prostate and breast health disparities.
    PLoS One. 2018;13:e0203855.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

62. PARTRIDGE SC, Newitt DC, Chenevert TL, Rosen MA, et al
    Diffusion-weighted MRI in Multicenter Trials of Breast Cancer.
    Radiology. 2019 Apr 2:190446. doi: 10.1148/radiol.2019190446.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: